YOLFTbeta
Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

REGN · NASDAQ · Healthcare / Biotechnology

955.47USD+4.28 (+0.45%)

Price History

Full chart

Market Stats

Previous Close951.19
Open952.47
Day Range942.00 – 961.94
52-Week Range590.83 – 975.49
Volume1.17M
Market Cap99.44B
P/E (TTM)21.25
Forward P/E15.36
EPS45.24
Dividend Yield0.39%
Beta0.10
50-Day Avg793.30
200-Day Avg737.54

About

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Leonard S. Schleifer M.D., Ph.D.
  • Employees15.41K
  • Headquarters777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707, USA
  • Websitehttps://www.regeneron.com

Leadership

  • Dr. Leonard S. Schleifer M.D., Ph.D.Co-Founder, President, CEO & Co-Chairman · b. 1953
  • Dr. George D. Yancopoulos M.D., Ph.D.Co-Founder, President, Chief Scientific Officer & Co-Chairman · b. 1960
  • Mr. Christopher R. Fenimore CPAExecutive VP of Finance & CFO · b. 1971
  • Mr. Joseph J. LaRosa J.D.Executive VP, General Counsel & Secretary · b. 1959
  • Dr. Andrew J. Murphy Ph.D.Executive VP of Research & Co-Chief Scientific Officer · b. 1958
  • Mr. Daniel P. Van PlewExecutive VP and GM of Industrial Operations & Product Supply · b. 1973
  • Mr. Rajesh AhujaSenior Vice President of Quality Assurance & Operations
  • Mr. Ryan SteinbergerExecutive VP, Chief Digital & Technology Officer
  • Mr. Ryan CroweSenior Vice President of Investor Relations & Strategic Analysis
  • Ms. Melissa LoznerSenior VP & Chief Compliance Officer

Financials

Income Statement

Currency: USD1990-12-311991-12-311992-12-311993-12-311994-12-311995-12-311996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue5.00M7.30M11.50M10.60M23.20M27.40M24.10M33.10M38.20M34.50M59.28M21.97M21.99M57.50M174.02M66.19M63.45M125.02M238.46M379.27M459.07M445.82M1.38B2.10B2.82B4.10B4.86B5.87B6.71B7.86B8.50B16.07B12.17B13.12B14.20B14.34B
Growth (%)-+46.00%+57.53%-7.83%+118.87%+18.10%-12.04%+37.34%+15.41%-9.69%+71.81%-62.93%+0.07%+161.49%+202.65%-61.96%-4.15%+97.05%+90.73%+59.05%+21.04%-2.89%+209.20%+52.69%+33.96%+45.55%+18.44%+20.82%+14.28%+17.18%+8.06%+89.14%-24.26%+7.76%+8.27%+0.99%
Cost of Revenue6.30M12.80M----1.10M2.60M5.00M3.60M15.57M6.51M6.48M6.68M151.31M25.06M22.74M227.99M923.00K15.93M2.09M4.22M84.45M155.35M205.02M392.71M299.69M397.06M434.10M782.20M1.36B2.72B1.71B883.70M1.97B2.10B
Gross Profit-1.30M-5.50M11.50M10.60M23.20M27.40M23.00M30.50M33.20M30.90M43.71M15.46M15.51M50.82M22.71M41.13M40.71M125.02M237.53M363.33M456.98M441.61M1.29B1.95B2.61B3.71B4.56B5.48B6.28B7.08B7.14B13.35B10.47B12.23B12.23B12.24B
Gross Margin-26.00%-75.34%100.00%100.00%100.00%100.00%95.44%92.15%86.91%89.57%73.74%70.38%70.52%88.39%13.05%62.14%64.16%100.00%99.61%95.80%99.54%99.05%93.87%92.62%92.73%90.43%93.83%93.24%93.53%90.05%84.04%83.05%85.99%93.26%86.13%85.35%
Operating Expense2.00M4.10M29.80M49.40M52.40M35.00M40.30M38.00M45.70M54.70M68.99M101.15M137.46M150.81M17.06M165.55M148.02M239.48M327.36M437.44M554.45M646.77M836.31M1.19B1.78B2.46B3.23B3.40B3.74B4.87B3.56B4.40B5.08B8.19B8.24B8.66B
Operating Income-3.30M-9.60M-18.30M-38.80M-29.20M-7.60M-17.30M-7.50M-12.50M-23.80M-25.28M-85.68M-121.95M-99.99M5.65M-124.42M-107.31M-114.45M-89.83M-74.10M-97.47M-205.16M457.71M760.03M838.43M1.25B1.33B2.08B2.53B2.21B3.58B8.95B5.39B4.05B3.99B3.58B
Operating Margin-66.00%-131.51%-159.13%-366.04%-125.86%-27.74%-71.78%-22.66%-32.72%-68.99%-42.64%-389.95%-554.63%-173.90%3.24%-187.97%-169.13%-91.55%-37.67%-19.54%-21.23%-46.02%33.20%36.11%29.74%30.51%27.38%35.41%37.77%28.10%42.09%55.67%44.24%30.85%28.10%24.95%
EBITDA-3.00M-8.80M-16.30M-35.70M-25.00M-1.70M-11.20M-9.30M-9.50M-20.40M-20.86M-79.61M-113.50M-91.51M69.24M-67.90M-76.52M-82.07M-78.54M-55.37M-77.78M-174.08M494.65M801.23M891.12M1.33B1.44B2.23B2.68B2.42B4.10B9.67B5.26B4.05B5.32B5.82B
EBITDA Margin-60.00%-120.55%-141.74%-336.79%-107.76%-6.20%-46.47%-28.10%-24.87%-59.13%-35.18%-362.29%-516.19%-159.16%39.79%-102.57%-120.60%-65.64%-32.94%-14.60%-16.94%-39.05%35.88%38.07%31.60%32.33%29.53%37.89%39.97%30.78%48.29%60.16%43.21%30.85%37.45%40.57%
Net Income-3.30M-4.50M-19.10M-39.90M-30.70M-23.50M-32.40M-11.60M-8.60M-23.10M-23.21M-76.18M-124.38M-107.46M41.70M-95.45M-102.34M-105.60M-82.71M-67.83M-104.47M-221.76M750.27M424.36M348.07M636.06M895.52M1.20B2.44B2.12B3.51B8.08B4.34B3.95B4.41B4.50B
Net Income Margin-66.00%-61.64%-166.09%-376.42%-132.33%-85.77%-134.44%-35.05%-22.51%-66.96%-39.16%-346.70%-565.66%-186.89%23.96%-144.19%-161.30%-84.46%-34.69%-17.88%-22.76%-49.74%54.43%20.16%12.34%15.50%18.42%20.41%36.42%26.91%41.35%50.25%35.64%30.14%31.07%31.41%
R&D----39.70M23.30M28.30M27.80M37.00M44.90M56.26M91.54M124.93M136.02M136.09M137.92M122.12M190.13M278.02M384.51M489.25M529.51M625.55M859.95M1.27B1.62B2.05B2.08B2.19B3.04B2.50B2.62B3.06B4.44B5.23B5.85B
R&D as % of Total Revenue----171.12%85.04%117.43%83.99%96.86%130.14%94.91%416.60%568.16%236.58%78.21%208.36%192.48%152.07%116.59%101.38%106.57%118.77%45.38%40.86%45.09%39.49%42.22%35.34%32.58%38.62%29.41%16.31%25.11%33.84%36.85%40.79%
Interest Expense05.20M00014.70M14.30M3.40M4.40M1.00M4.58M12.16M9.44M4.46M48.23M41.02M16.55M12.04M7.75M2.34M9.12M21.28M45.30M46.44M37.37M14.24M7.20M25.12M28.20M30.20M56.90M57.30M59.40M73.00M55.20M43.80M
Interest Expense % of Total Revenue0.00%71.23%0.00%0.00%0.00%53.65%59.34%10.27%11.52%2.90%7.72%55.34%42.91%7.76%27.71%61.97%26.08%9.63%3.25%0.62%1.99%4.77%3.29%2.21%1.33%0.35%0.15%0.43%0.42%0.38%0.67%0.36%0.49%0.56%0.39%0.31%

Balance Sheet

Currency: USD1990-12-311991-12-311992-12-311993-12-311994-12-311995-12-311996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets25.40M114.00M97.90M117.60M94.20M93.80M137.60M168.40M156.90M137.00M208.27M495.40M391.57M479.56M473.11M423.50M585.09M936.26M670.04M741.20M1.09B1.32B2.08B2.95B3.87B5.61B6.97B8.76B11.73B14.81B17.16B25.43B29.21B33.08B37.76B40.56B
Total Liabilities13.20M7.80M10.70M19.20M27.10M25.90M30.70M29.50M25.70M27.50M26.14M229.04M245.59M341.91M290.56M309.50M368.47M475.99M251.19M344.44M561.62M837.85M835.11M998.94M1.33B1.95B2.52B2.62B2.98B3.72B6.14B6.67B6.55B7.11B8.41B9.30B
Total Equity12.20M106.20M87.20M98.40M67.10M67.90M106.90M138.90M131.20M109.50M182.13M266.36M145.98M137.64M182.54M114.00M216.62M460.27M418.85M396.76M527.82M485.73M1.25B1.95B2.54B3.65B4.45B6.14B8.76B11.09B11.03B18.77B22.66B25.97B29.35B31.26B
Cash21.80M26.20M16.40M12.50M23.60M32.70M34.50M28.90M19.80M23.70M30.98M247.39M80.08M118.28M101.23M184.51M237.88M498.93M247.80M207.07M112.57M483.61M230.28M535.61M648.72M809.10M535.20M812.73M1.47B1.62B2.19B2.89B3.11B2.73B2.49B3.12B
Total Debt-2.80M6.80M7.50M12.30M9.50M8.70M5.60M4.20M4.10M2.68M200.58M200.15M213.82M200.00M200.00M200.00M202.29M5.09M109.02M160.03M435.53M457.33M505.51M496.97M815.53M481.13M1.17B799.30M713.90M3.61B2.70B2.70B2.70B2.70B2.71B
Net Debt-21.80M-23.40M-9.60M-5.00M-11.30M-23.20M-25.80M-23.30M-15.60M-19.60M-28.30M-46.82M120.07M95.53M98.77M15.49M-37.88M-296.63M-242.70M-98.05M47.46M-48.08M227.05M-30.10M-189.66M-433.59M-54.08M-109.28M-759.20M-903.90M502.00M-185.90M-404.50M-27.10M216.20M-412.20M

Cash Flow

Currency: USD1991-12-311992-12-311993-12-311994-12-311995-12-311996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-6.80M-17.20M-30.10M-20.50M-18.20M-20.30M-6.10M-10.20M-13.80M-27.91M-57.32M-110.52M-6.13M-16.91M-30.30M23.07M27.37M-89.09M-72.23M96.34M-141.68M-74.61M588.60M752.43M1.33B1.49B1.31B2.20B2.43B2.62B7.08B5.01B4.59B4.42B4.98B
Investing Cash Flow-77.60M8.20M-23.60M31.90M7.40M-44.30M-38.90M2.40M17.50M-57.68M-75.39M-58.52M-63.84M-4.58M115.49M-155.10M-85.72M30.82M146.00K-434.15M128.47M-81.07M-355.45M-420.78M-907.60M-1.05B-1.01B-1.46B-2.03B-70.60M-5.38B-3.78B-3.19B-2.47B-629.10M
Financing Cash Flow91.50M-800.00K49.80M-200.00K19.90M66.30M39.40M-1.40M300.00K92.87M349.12M1.72M108.18M4.44M4.08M185.40M319.40M-192.86M31.36M243.31M384.25M-97.65M72.19M-218.55M-262.80M-700.39M-24.40M-77.10M-252.10M-1.97B-1.01B-1.01B-1.79B-2.20B-3.72B
Capital Expenditure1.00M2.10M10.20M6.90M3.30M8.60M2.10M3.00M5.70M6.50M8.22M34.37M29.66M6.17M4.96M2.81M18.45M34.86M97.32M99.69M57.22M49.34M156.32M333.01M677.93M511.90M272.60M383.10M429.60M614.60M551.90M590.10M926.40M755.90M898.40M
Free Cash Flow-7.80M-19.30M-40.30M-27.40M-21.50M-28.90M-8.20M-13.20M-19.50M-34.41M-65.54M-144.89M-35.79M-23.08M-35.26M20.26M8.93M-123.94M-169.55M-3.35M-198.90M-123.95M432.27M419.43M652.85M974.00M1.03B1.81B2.00B2.00B6.53B4.42B3.67B3.66B4.08B
Dividends Paid-------------------0000294.55M547.47M500.18M358.69M-----00370.30M
FCF to OCF114.71%112.21%133.89%133.66%118.13%142.36%134.43%129.41%141.30%123.27%114.35%131.10%583.55%136.51%116.39%87.82%32.61%139.13%234.73%-3.47%140.38%166.12%73.44%55.74%49.06%65.55%79.14%82.55%82.32%76.52%92.21%88.23%79.83%82.90%81.96%
Dividend Paid to FCF-------------------0.00%0.00%0.00%0.00%70.23%83.86%51.35%34.67%-----0.00%0.00%9.07%

Earnings

Report DateAug 3, 1994Oct 31, 1994Feb 13, 1995May 3, 1995Aug 1, 1995Nov 14, 1995Feb 5, 1996May 3, 1996Jul 29, 1996Oct 23, 1996Feb 5, 1997May 6, 1997Aug 1, 1997Mar 31, 1998Jun 30, 1998Sep 30, 1998Dec 31, 1998Mar 31, 1999Jul 30, 1999Oct 28, 1999Feb 4, 2000Apr 28, 2000Jul 27, 2000Oct 24, 2000Jan 25, 2001May 1, 2001Jul 31, 2001Oct 22, 2001Jan 31, 2002Apr 29, 2002Jul 30, 2002Oct 31, 2002Jan 30, 2003May 5, 2003Aug 1, 2003Oct 29, 2003Feb 23, 2004Apr 26, 2004Jul 26, 2004Oct 28, 2004Feb 22, 2005Apr 28, 2005Aug 4, 2005Nov 3, 2005Feb 24, 2006May 3, 2006Aug 3, 2006Nov 6, 2006Mar 1, 2007May 2, 2007Aug 1, 2007Nov 6, 2007Feb 27, 2008May 1, 2008Jul 31, 2008Nov 4, 2008Feb 26, 2009Apr 30, 2009Aug 4, 2009Nov 3, 2009Feb 18, 2010Apr 29, 2010Jul 28, 2010Oct 28, 2010Feb 17, 2011May 3, 2011Jul 28, 2011Oct 27, 2011Feb 13, 2012Apr 26, 2012Jul 25, 2012Oct 24, 2012Feb 14, 2013May 3, 2013Aug 6, 2013Nov 5, 2013Feb 11, 2014May 8, 2014Aug 5, 2014Nov 4, 2014Feb 10, 2015May 7, 2015Aug 4, 2015Nov 4, 2015Feb 9, 2016May 5, 2016Aug 4, 2016Nov 4, 2016Feb 9, 2017May 4, 2017Aug 3, 2017Nov 8, 2017Feb 8, 2018May 3, 2018Aug 2, 2018Nov 6, 2018Feb 6, 2019May 7, 2019Aug 6, 2019Nov 5, 2019Feb 6, 2020May 5, 2020Aug 5, 2020Nov 5, 2020Feb 5, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Feb 4, 2022May 4, 2022Aug 3, 2022Nov 3, 2022Feb 3, 2023May 4, 2023Aug 3, 2023Nov 2, 2023Feb 2, 2024May 2, 2024Aug 1, 2024Oct 31, 2024Feb 4, 2025Apr 29, 2025Aug 1, 2025Oct 28, 2025Jan 30, 2026Apr 29, 2026Jul 30, 2026Oct 30, 2026
EPS Estimate-0.58-0.36-0.39-0.35-0.24-0.39-0.30-0.36-0.40-0.34-0.33-0.38-0.21------0.25-0.20-0.21-0.12-0.13-0.30-0.34-0.43-0.52-0.53-0.63-0.64-0.64-0.77-0.84-0.84-0.50-0.53-0.53-0.46-0.30-0.42-0.36-0.36-0.53-0.66-0.64-0.61-0.56-0.56-0.51-0.45-0.43-0.29-0.47-0.36-0.29-0.28-0.30-0.31-0.28-0.20-0.34-0.46-0.38-0.35-0.32-0.32-0.40-0.74-0.60-0.230.471.061.241.431.831.892.082.262.292.572.832.692.783.203.362.552.652.703.053.073.183.824.574.344.685.065.605.525.426.407.176.095.976.998.298.6817.719.9420.309.808.769.4810.019.569.9010.7810.7510.1010.6211.7011.198.488.449.6410.758.908.0013.76
EPS Actual-0.54-0.21-0.30-0.22-0.22-0.32-0.38-0.35-0.31-0.35-0.32-0.23-0.16-0.120.07-0.04-0.18-0.29-0.25-0.16-0.04-0.23-0.08-0.09-0.23-0.35-0.34-0.46-0.65-0.58-0.69-0.75-0.81-0.68-0.58-0.52-0.351.06-0.26-0.200.05-0.37-0.38-0.62-0.53-0.36-0.41-0.48-0.51-0.46-0.41-0.54-0.19-0.15-0.22-0.27-0.40-0.22-0.19-0.01-0.46-0.38-0.31-0.41-0.17-0.49-0.69-0.68-0.580.160.901.891.471.781.732.402.242.262.472.522.792.882.893.472.832.572.823.133.042.924.173.995.234.675.455.876.844.456.026.677.506.607.168.369.539.8925.8015.3723.7211.499.7711.1412.5610.0910.2411.5911.869.5511.5612.4612.078.2212.8911.8311.449.4712.5318.43
Surprise6.90%41.67%23.08%37.14%8.33%17.95%-26.67%2.78%22.50%-2.94%3.03%39.47%23.81%-----0.00%20.00%80.95%-91.67%38.46%70.00%32.35%18.60%34.62%13.21%-3.17%9.38%-7.81%2.60%3.57%19.05%-16.00%1.89%33.96%330.43%13.33%52.38%113.89%-2.78%28.30%6.06%17.19%40.98%26.79%14.29%0.00%-2.22%4.65%-86.21%59.57%58.33%24.14%3.57%-33.33%29.03%32.14%95.00%-35.29%17.39%18.42%-17.14%46.88%-53.13%-72.50%8.11%3.33%169.57%91.49%78.30%18.55%24.48%-5.46%26.98%7.69%0.00%7.86%-1.95%-1.41%7.06%3.96%8.44%-15.77%0.78%6.42%15.93%-0.33%-4.89%31.13%4.45%14.44%7.60%16.45%16.01%22.14%-19.38%11.07%4.22%4.60%8.37%19.93%19.60%14.96%13.94%45.68%54.63%16.85%17.24%11.53%17.51%25.47%5.54%3.43%7.51%10.33%-5.45%8.85%6.50%7.86%-3.07%52.73%22.72%6.42%6.40%56.63%33.94%
Timing----Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market----------------Pre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-After-hoursAfter-hoursPre-market-Pre-marketPre-marketPre-marketPre-market-Pre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap99.44B
Enterprise Value89.39B
Trailing P/E21.25
Forward P/E15.36
PEG Ratio1.58
Price / Sales5.89
Price / Book2.87
EPS45.24
Book Value333.93
Revenue (TTM)16.90B
Gross Profit (TTM)7.90B
EBITDA5.65B
Profit Margin28.51%
Operating Margin40.46%
Return on Equity14.95%
Return on Assets7.59%
Shares Outstanding101.63M
Shares Float96.32M
Beta0.10
Dividend Yield0.39%
Dividend Rate3.76
Payout Ratio7.13%

Analyst Ratings

Buy
Based on 28 analystsTarget 969.59
  • Strong Buy
    15
  • Buy
    4
  • Hold
    8
  • Sell
    1

Ownership Breakdown

Institutions
93.25%
Insiders
2.08%
Retail / Other
4.67%

Top Institutional Holders

  • BlackRock Inc
    9.11M8.81%
  • Vanguard Capital Management, LLC
    6.63M6.41%
  • Dodge & Cox
    4.87M4.71%
  • State Street Corp
    4.83M4.67%
  • Amvescap Plc.
    3.94M3.81%
  • JPMorgan Chase & Co
    3.77M3.65%
  • Vanguard Portfolio Management, LLC
    3.18M3.07%
  • Franklin Templeton Inc
    2.77M2.68%
  • Geode Capital Management, LLC
    2.63M2.54%
  • Nuveen, LLC
    2.02M1.95%
  • Loomis, Sayles & Company LP
    1.86M1.80%
  • T. Rowe Price Associates, Inc.
    1.53M1.48%
  • Morgan Stanley - Brokerage Accounts
    1.40M1.35%
  • Bank of America Corp
    1.29M1.25%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    3.21M3.10%
  • Dodge & Cox Stock I
    3.09M2.99%
  • Vanguard 500 Index Investor
    2.57M2.49%
  • Invesco QQQ Trust
    2.10M2.03%
  • iShares Core S&P 500 ETF
    1.30M1.26%
  • Fidelity 500 Index
    1.30M1.25%

Dividends

20263×
0.94Aug 18, 20260.94May 20, 20260.94Feb 20, 2026
20254×
0.88Nov 20, 20250.88Aug 18, 20250.88May 20, 20250.88Feb 20, 2025